Eikon Therapeutics IPO: Filing to Boost Cancer Drug Pipeline
Eikon Therapeutics IPO aims to raise capital to fund its innovative pipeline of cancer treatments, advancing drug development and clinical trials in a
Evommune biotechnology IPO Raises $150 Million to Tackle
Evommune biotechnology IPO marks a key milestone as the firm raises $150 million to advance its research, expand its pipeline, and develop treatments for
Lila Sciences Secures New Funding to Advance AI-Driven Drug and Material Development
Lila Sciences, a biotechnology firm specializing in the development of novel drugs and materials through artificial intelligence, has announced a new round of funding. The company’s latest investment was led…